Pfizer News and Research RSS Feed - Pfizer News and Research

Second-generation antibiotic shows promise against common bacterial infections

Second-generation antibiotic shows promise against common bacterial infections

Researchers led by St. Jude Children's Research Hospital scientists have developed a second-generation antibiotic that shows early effectiveness against common bacterial infections that pose a serious health threat to children and adults. [More]
Kidney function plays critical role in sepsis patients

Kidney function plays critical role in sepsis patients

Researchers at Duke Medicine have determined that kidney function plays a critical role in the fate of patients being treated for sepsis, a potentially life-threatening complication of an infection. [More]
FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

Protein Sciences Corporation announced that on May 12, 2015 the U.S. Food and Drug Administration licensed its Pearl River, NY manufacturing facility for the commercial manufacturing of Flublok influenza vaccine. Flublok is the world's first licensed influenza vaccine made using modern recombinant technology. [More]
New landmark study to examine role of cocoa flavanols in maintaining cardiovascular health

New landmark study to examine role of cocoa flavanols in maintaining cardiovascular health

Recognizing that heart health is one of the world's most significant public health challenges, Mars, Incorporated, in collaboration with Brigham and Women's Hospital (BWH), a teaching affiliate of Harvard Medical School, is launching a five-year landmark study to examine the role of cocoa flavanols, plant-derived bioactives from the cacao bean, in helping people maintain cardiovascular health. [More]
UNC-Chapel Hill, GSK partner to find cure for HIV/AIDS

UNC-Chapel Hill, GSK partner to find cure for HIV/AIDS

The University of North Carolina at Chapel Hill, a leading global public research university with significant expertise in HIV basic and clinical research, and GSK, a global, research-based pharmaceutical and healthcare company with a legacy of success in developing treatments for HIV, today announced the creation of the dedicated HIV Cure center and a jointly owned new company that will focus on discovering a cure for HIV/AIDS. [More]
ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

ViiV Healthcare today announced the start of a Phase III clinical trial programme to evaluate the safety and efficacy of dolutegravir (Tivicay) and rilpivirine (Edurant) as maintenance therapy for adult patients with HIV. [More]
23andMe, Pfizer jointly launch Lupus Research Study

23andMe, Pfizer jointly launch Lupus Research Study

23andMe, Inc., the leading personal genetics company, today announced the launch of the Lupus Research Study in collaboration with Pfizer Inc. The companies aim to enroll 5,000 individuals with systemic lupus erythematosus, more commonly known as lupus, into the study to help better understand the genetics of lupus. [More]
FDA grants tentative approval to Amerigen's ANDA for generic version of Toviaz

FDA grants tentative approval to Amerigen's ANDA for generic version of Toviaz

Amerigen Pharmaceuticals Limited today announced that the U.S. Food and Drug Administration has granted tentative approval to the Company's Abbreviated New Drug Application (ANDA) for a generic version of Toviaz (Fesoterodine Fumarate Extended-release Tablets, 4mg and 8mg). [More]
Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Phase 3 results presented today at The International Liver Congress 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence. [More]
New drug combination shows promise in patients with metastatic melanoma

New drug combination shows promise in patients with metastatic melanoma

Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug. [More]
Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Rhythm, a biopharmaceutical company, and Actavis plc, a leading global pharmaceutical company, announced today the initiation of a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Rhythm's ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes. [More]
EpiPen (epinephrine) emergency kits now available at Montreal Bell Centre for treating severe allergies

EpiPen (epinephrine) emergency kits now available at Montreal Bell Centre for treating severe allergies

Pfizer Canada Inc., the distributor of EpiPen, and the Montreal Bell Centre are pleased to announce that EpiPen (epinephrine) emergency kits are now available at the Bell Centre, home of the Montreal Canadiens hockey team. The new partnership strives to offer a safeguarded environment for visitors at risk of serious allergic reactions during hockey games, concerts and other entertainment events. [More]
AAHRPP accredits three more organizations

AAHRPP accredits three more organizations

The Association for the Accreditation of Human Research Protection Programs today announced that it has accredited three more organizations, including the first historically black college and university medical school and a fourth hospital in Taiwan. [More]
Scientists identify mystery behind cell-signaling breakdown that causes heart failure

Scientists identify mystery behind cell-signaling breakdown that causes heart failure

Working with lab animals and human heart cells, scientists from Johns Hopkins and other institutions have identified what they describe as "the long-sought culprit" in the mystery behind a cell-signaling breakdown that triggers heart failure. The condition, which affects nearly 6 million Americans and 23 million people worldwide, is marked by progressive weakening and stiffening of the heart muscle and the organ's gradual loss of blood-pumping ability. [More]
Keas announces launch of Health Hub for self-insured employers

Keas announces launch of Health Hub for self-insured employers

Keas, the health management leader, today announced the launch of Health Hub, the first Health Management platform for self-insured employers. [More]

Columbia Laboratories' revenues increase 11% to $32.5 million in 2014

Columbia Laboratories, Inc., today announced financial results for the three- and twelve-month periods ended December 31, 2014. [More]
Global breast cancer therapeutics market estimated to reach $13.38 billion in 2018

Global breast cancer therapeutics market estimated to reach $13.38 billion in 2018

Despite the availability of approximately 25 drugs for the treatment of breast cancer, the unmet need in the global market is vast. To address this drawback, pharmaceutical companies have established a robust pipeline that currently has about 52 drugs in development. While chemotherapy remains the most important class of drugs for breast cancer treatment, the trend toward targeted drugs is on the rise. [More]
Brazil's first open-access research facility to be established at UNICAMP

Brazil's first open-access research facility to be established at UNICAMP

Open-access research into drug discovery has arrived in South America, with a ground-breaking collaboration between leading scientists in North America, Europe and Brazil to provide completely free and open research results to the world. [More]
New blood thinner reduces stroke risk in patients with atrial fibrillation

New blood thinner reduces stroke risk in patients with atrial fibrillation

Patients with high-risk atrial fibrillation, or AFib, often require one drug to regulate heart rhythm and a second drug to thin their blood and reduce the risk of stroke. [More]
Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

In patients with advanced thyroid cancer, sunitinib, a drug approved for treatment of several other cancers, showed significant cancer-fighting activity t, a new phase 2 clinical trial has found. Results of the single-center study will be presented Sunday at the Endocrine Society's 97th annual meeting in San Diego. [More]
Advertisement
Advertisement